664 related articles for article (PubMed ID: 18060032)
1. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Gao SP; Mark KG; Leslie K; Pao W; Motoi N; Gerald WL; Travis WD; Bornmann W; Veach D; Clarkson B; Bromberg JF
J Clin Invest; 2007 Dec; 117(12):3846-56. PubMed ID: 18060032
[TBL] [Abstract][Full Text] [Related]
2. IL-6 involvement in epithelial cancers.
Schafer ZT; Brugge JS
J Clin Invest; 2007 Dec; 117(12):3660-3. PubMed ID: 18060028
[TBL] [Abstract][Full Text] [Related]
3. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
Clay TD; Russell PA; Do H; Sundararajan V; Conron M; Wright GM; Solomon B; Dobrovic A; McLachlan SA; Moore MM
Med Oncol; 2017 Sep; 34(10):175. PubMed ID: 28879441
[TBL] [Abstract][Full Text] [Related]
4. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.
Berishaj M; Gao SP; Ahmed S; Leslie K; Al-Ahmadie H; Gerald WL; Bornmann W; Bromberg JF
Breast Cancer Res; 2007; 9(3):R32. PubMed ID: 17531096
[TBL] [Abstract][Full Text] [Related]
5. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Song L; Rawal B; Nemeth JA; Haura EB
Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
[TBL] [Abstract][Full Text] [Related]
6. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation.
Leslie K; Gao SP; Berishaj M; Podsypanina K; Ho H; Ivashkiv L; Bromberg J
Breast Cancer Res; 2010; 12(5):R80. PubMed ID: 20929542
[TBL] [Abstract][Full Text] [Related]
7. STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.
Takata S; Takigawa N; Segawa Y; Kubo T; Ohashi K; Kozuki T; Teramoto N; Yamashita M; Toyooka S; Tanimoto M; Kiura K
Lung Cancer; 2012 Jan; 75(1):24-9. PubMed ID: 21684622
[TBL] [Abstract][Full Text] [Related]
8. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
[TBL] [Abstract][Full Text] [Related]
9. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.
Wang Y; van Boxel-Dezaire AH; Cheon H; Yang J; Stark GR
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16975-80. PubMed ID: 24082147
[TBL] [Abstract][Full Text] [Related]
10. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
11. Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway.
Kuang Y; Guo W; Ling J; Xu D; Liao Y; Zhao H; Du X; Wang H; Xu M; Song H; Wang T; Jing B; Li K; Hu M; Wu W; Deng J; Wang Q
Cell Death Dis; 2019 Apr; 10(4):297. PubMed ID: 30931929
[TBL] [Abstract][Full Text] [Related]
12. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
13. Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells.
Wang HC; Yeh HH; Huang WL; Lin CC; Su WP; Chen HH; Lai WW; Su WC
Mol Endocrinol; 2011 Jul; 25(7):1145-58. PubMed ID: 21546410
[TBL] [Abstract][Full Text] [Related]
14. p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway.
Ozenne P; Dayde D; Brambilla E; Eymin B; Gazzeri S
Oncogene; 2013 Feb; 32(8):1050-8. PubMed ID: 22450744
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells.
Yang Y; Wang W; Chang H; Han Z; Yu X; Zhang T
J Cell Mol Med; 2019 Nov; 23(11):7331-7341. PubMed ID: 31507089
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.
Sriuranpong V; Park JI; Amornphimoltham P; Patel V; Nelkin BD; Gutkind JS
Cancer Res; 2003 Jun; 63(11):2948-56. PubMed ID: 12782602
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
[TBL] [Abstract][Full Text] [Related]
19. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
20. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
